VRPX Insider Trading (Virpax Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $115,536.75
Insider Selling (Last 12 Months): $0.00
Virpax Pharmaceuticals Share Price & Price History
Current Price: $1.30
Price Change: ▼ Price Decrease of -0.045 (-3.36%)
As of 05/16/2022 04:03 PM ET
Warning: The Last Value Play Gone After August?
From Oxford Club | Ad
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward.
Get the Details Now.
Virpax Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/22/2021 | Jerrold Sendrow | Director | Buy | 3,900 | $3.92 | $15,288.00 | |  |
| 11/18/2021 | Anthony P. Mack | CEO | Buy | 25,125 | $3.99 | $100,248.75 | | |
| 2/17/2021 | Thani Jambulingam | Director | Buy | 100 | $7.16 | $716.00 | 100 | |
Renowned Economist issues startling prediction | America's Future
From Legacy Research | Ad
According to former Goldman Sachs executive, Nomi Prins…
Americans who are hoping for a ‘return to normal’ are going to be shocked when they see what happens next in America.
She says, “If you’re betting your job, savings, or retirement accounts on a return to ‘normal’ you’re about to be left behind by a brand-new crisis few see coming.”
Click here now to see America’s next crisis.
Virpax Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/13/2022 | Renaissance Technologies LLC | 156,600 | $0.35M | 0.0% | N/A | 1.337% |  |
| 5/13/2022 | Vanguard Group Inc. | 341,977 | $0.76M | 0.0% | +4.5% | 2.918% | |
| 5/13/2022 | Warberg Asset Management LLC | 17,710 | $39K | 0.0% | N/A | 0.151% | |
| 5/12/2022 | Citigroup Inc. | 12,179 | $27K | 0.0% | N/A | 0.104% | |
| 2/14/2022 | Citadel Advisors LLC | 98,046 | $0.34M | 0.0% | N/A | 0.837% | |
| 2/11/2022 | Geode Capital Management LLC | 47,671 | $0.16M | 0.0% | +374.6% | 0.407% | |
| 2/8/2022 | Northern Trust Corp | 15,221 | $52K | 0.0% | N/A | 0.130% | |
| 11/17/2021 | Altium Capital Management LP | 271,846 | $1.31M | 0.3% | N/A | 2.320% | |
| 11/16/2021 | National Asset Management Inc. | 18,600 | $90K | 0.0% | N/A | 0.159% | |
| 11/16/2021 | Two Sigma Investments LP | 25,715 | $0.12M | 0.0% | N/A | 0.220% | |
| 11/12/2021 | Geode Capital Management LLC | 10,045 | $48K | 0.0% | N/A | 0.086% | |
| 11/2/2021 | Cambridge Investment Research Advisors Inc. | 19,420 | $93K | 0.0% | N/A | 0.166% | |
| 9/17/2021 | Virtu Financial LLC | 23,625 | $0.11M | 0.0% | N/A | 0.468% | |
| 8/16/2021 | Sabby Management LLC | 154,737 | $0.70M | 0.1% | -22.6% | 3.120% | |
| 8/12/2021 | Saltoro Capital LP | 17,615 | $80K | 0.0% | -34.8% | 0.355% | |
| 5/14/2021 | HN Saltoro Capital LP | 27,000 | $0.13M | 0.0% | N/A | 0.546% | |
Data available starting January 2016
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More on Virpax Pharmaceuticals
Volume
14,677 shs
Average Volume
193,816 shs
Market Capitalization
$15.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
4.55
Who are the company insiders with the largest holdings of Virpax Pharmaceuticals?
Who are the major institutional investors of Virpax Pharmaceuticals?
Which institutional investors are buying Virpax Pharmaceuticals stock?
Within the previous quarter, VRPX stock was acquired by institutional investors including:
- Renaissance Technologies LLC
- Warberg Asset Management LLC
- Vanguard Group Inc.
- Citigroup Inc.
Within the last year, these company insiders have bought Virpax Pharmaceuticals stock:
- Thani Jambulingam (Director)
- Anthony P Mack (CEO)
- Jerrold Sendrow (Director)
Learn More investors buying Virpax Pharmaceuticals stock.
